Navigation Links
Concerned Stockholders Launch Save Vermillion! Website: www.savevrml.com
Date:2/1/2013

PHILADELPHIA, Feb. 1, 2013 /PRNewswire/ -- George Bessenyei , Gregory V. Novak , and Robert S. Goggin (the "Group") today launched their website, www.savevrml.com, to provide all stockholders access to relevant information concerning Vermillion Inc.'s (the "Company" or "Vermillion") contested 2012 Annual Stockholder meeting (the "2012 Annual Meeting").

The road to forcing Vermillion's Board to schedule the annual meeting has been anything but easy, short, or smooth.  Almost a year ago, on February 15, 2012, the Group announced its intention to nominate Robert S. Goggin as Director Nominee for the 2012 Annual Meeting. After a series of dodge ball tactics by the Board and Gail Page , more recently, on January 9, 2013, Bessenyei filed a complaint in the Delaware Chancery Court ("Court"), asking the Court to order the Company to call and hold an annual meeting of stockholders at the earliest practicable date. This maneuver was necessary, given what the Group believes was management's stonewalling, to finally force the Company to abide by its own Bylaws, Delaware law and to avoid a NASDAQ delisting process, and call the 2012 meeting.  After the complaint was filed, the Company finally set the meeting date for March 21st, 2013.

In order to provide more information to stockholders, the Group today launched its website. Major topics include: 

  • Robert S. Goggin 's Five Point Turnaround Plan for Vermillion
  • Comprehensive analysis of OVA1 and its market potential
  • Biography of Group members
  • Timeline of events leading to the 2012 Annual Meeting
  • Compensati
    '/>"/>

SOURCE Concerned Vermillion Stockholders
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Mangrove Partners Sends Letter to Stockholders of Nabi Biopharmaceuticals
2. Bacterin Receives Letter From NYSE MKT LLC Regarding Timely Notice of Record Date for 2012 Annual Meeting of Stockholders
3. Generex Announces Date of Annual Stockholders Meeting
4. Amarantus BioScience Launches New Website
5. Touch Medical Media Splits From Touch Briefings, Launches a Series of Cutting Edge, Free to Access, Educational Resources and Signs an Updated Media Partnership With ECCO, The European CanCer Organisation Representing 60,000 Oncology Professionals
6. Find New Cancer Treatments at cureLauncher
7. New York Microscope Launches New Website http://www.NYscopes.com
8. MDA Launches Clinical Network to Speed Myotonic Dystrophy Research
9. DuPont Pioneer Launches Next Generation T Series Soybeans
10. MedZilla.com Launches New Site Design for 2013, Slick New Interface Impresses
11. Nerium Announcing Launch of New Blog Sites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Nova Scotia (PRWEB) February 27, 2015 ... stage vaccine and immunotherapy company, today announced that ... its application for Fast Track designation and Phase ... vaccines, in conjunction with the mutual co-development agreement ... previously obtained Fast Track designation for the DPX-Survivac. ...
(Date:2/27/2015)... 2015 FamilyFarms Group is pleased to ... State Line Farms, received the 2015 Tomorrow’s Top Producer ... the age of 35, who has demonstrated excellence in ... to win the Tomorrow's Top Producer Horizon Award. Every ... Top Producer Award and learning from their experiences. It ...
(Date:2/26/2015)... S&P Capital IQ (MHFI) announced today that ... MabVax Therapeutics Holdings Inc . MabVax ... company focused on the development of vaccine and antibody-based ... of cancer. MabVax has discovered a pipeline of human ... generated by patients who have been immunized against targeted ...
(Date:2/26/2015)... Mass., Feb. 26, 2015   Synageva BioPharma ... biopharmaceutical company developing therapeutic products for rare disorders, ... provided 2015 goals, other key objectives, and financial ... call today at 4:30 p.m. EST to review ... update.  To participate in today,s call by telephone, ...
Breaking Biology Technology:Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9
... 2010 ... ... ... Results are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
... Inc. (OTC Bulletin Board: CSBR ), a ... and tumor specific data to enhance the value of ... joined the management team as the Chief Executive Officer ... Dr. Ronnie Morris will join the management team as ...
... Oct. 28 Q3 2010 Change on a reported ... 9 months 2010Change on a reported ... sales , €7,821m+5.7% , -1.7% , €22,989m+4.8% , ... €7,377m+8.7% , +6.0%Business EPS(1)€1.89+8.6%-2.3%€5.65+8.7%+6.0% In order to facilitate an understanding ...
Cached Biology Technology:Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 2Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 3Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 4Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 5Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 6Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 7Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 8Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 9Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 10Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 11Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 12Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 13Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 14Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 15Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 16Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 17Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 18Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 19Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 20Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 21Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 22Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 23Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 24Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 25Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 26Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 27Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 28Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 29Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 30Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 31Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 32Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 33Champions Biotechnology Reports Additions to its Management Team 2Champions Biotechnology Reports Additions to its Management Team 3Champions Biotechnology Reports Additions to its Management Team 4
(Date:2/5/2015)... PARK, North Carolina , 5. Februar ... 35. Jahr als spezialisiertes Logistikunternehmen und hat ... als einzige klinische Logistikfirma (Clinical Logistics Organization ... Kernbotschaft der neuen Kampagne lautet First ... Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... --  Epic Sciences , a precision diagnostics company dedicated to ... Prahalad , Ph.D., president and CEO, is scheduled to present ... Silicon Valley, which is taking place at the Computer History ... January 26-28, 2015. Dr. Prahalad will give ... year, Epic Sciences was a finalist in the PMWC,s Most ...
(Date:2/5/2015)... , Jan. 27, 2015   ... of globally deployed, innovative test solutions for ... the delivery of its TS-323 GENASYS ... Systems Company (LMSSC). GENASYS is a high-performance ... of mission-critical applications that require performance functional ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... research shows that a protein made by a cancer-causing virus ... in fact critically needed by the virus to initiate an ... human T lymphotropic virus type 1 (HTLV-1) and a protein ... virus' so-called accessory proteins, proteins that earlier studies done in ...
... rusty crayfish - a voracious, bullying exotic that has visited ... met its match. , Since its introduction to Wisconsin waters ... of lakes and streams, clear cutting the underwater forests that ... body of water after another and scooping up fish eggs ...
... a type of amoeba acts as an incubator for ... environments this discovery has implications for the infection control ... Acanthamoeba polyphagam commonly eats and digests environmental bacteria. It ... being digested by the amoeba, MRSA survives and replicates ...
Cached Biology News:Cancer virus protein needed for successful infection 2Study shows hope for ridding lakes of clawed invader 2Study shows hope for ridding lakes of clawed invader 3
The VersArray hybridization chamber is used for manual (coverslip) hybridization of microarrays. The chamber accommodates 2 slides and is watertight to allow incubation of slides in a water bath. Dim...
... state-of-the-art separation system using the asymmetric flow ... integrates easily with Wyatts multi-angle light scattering ... as the Optilab DSP. The combined system ... of the particles/molecules separated by the AFFF ...
Monoclonal antibodies conjugated with rhodamine...
... and lightweight, the Moticam 2300 camera (MC2300) ... eyepiece, eyetube, or trinocular port. Included in ... Plug-and-Play Images 2.0ML software offers quick and ... to maximize resolution for examination or documentation ...
Biology Products: